OncoGenex Pharmaceuticals (NASDAQ:OGXI)

CAPS Rating: 2 out of 5

Results 1 - 15 of 15

Recs

0
Member Avatar oscillation (< 20) Submitted: 2/27/2015 12:25:50 AM : Outperform Start Price: $2.30 OGXI Score: +41.08

nev

Recs

3
Member Avatar zzlangerhans (99.66) Submitted: 1/19/2015 10:40:56 PM : Outperform Start Price: $2.29 OGXI Score: +36.09

I hadn't revisited OncoGenex in the months since I pillaged the stock to the tune of eleven grand before it blew up on failure of the SYNERGY trial in April. I guess I figured it was better to leave well enough alone, which was a wise decision since the share price continued to decline to new lows over the summer. The other day Portefeuille suggested I take another look, and it does seem the share price has likely bottomed ahead of phase III catalysts expected later this year. Earlier this month the AFFINITY phase III trial of custirsen + Jevtana + prednisone as second-line therapy for advanced CRPC passed its interim analysis and will proceed to completion with topline data expected in late 2015 or early 2016. The ENSPIRIT phase III trial of custirsen + docetaxel as second-line therapy for advanced or metastatic NSCLC has passed its first interim analysis. The company plans to gamble on the second interim analysis by setting a more rigorous bar for success that will allow the company to reduce enrollment in the trial if the interim is passed. My prediction? Fail. However, as long as the timing of that second analysis in Q2 can be predicted so that zzporte is no longer holding shares, it seems likely that we'll be able to escape at a price somewhat higher than the current sub-cash level.

Recs

0
Member Avatar wassercom (74.78) Submitted: 10/13/2014 9:40:08 PM : Outperform Start Price: $2.20 OGXI Score: +35.38

Placebo arm of the last Phase III trial was poorly designed.

Recs

0
Member Avatar a410traveler (54.71) Submitted: 9/14/2014 4:47:48 PM : Outperform Start Price: $3.15 OGXI Score: -3.00

Strong pipeline of cancer fighting drugs.

Recs

0
Member Avatar Investinguppy (< 20) Submitted: 6/17/2014 11:01:54 PM : Outperform Start Price: $3.63 OGXI Score: -18.95

Very risky play, it seems their drugs, which were so promising a few years ago, are being eclipsed by new medications.

Still hold some promise for second and third line cancer treatment to overcome resistance.

Recs

0
Member Avatar TerryFool (62.20) Submitted: 4/4/2014 3:50:32 PM : Outperform Start Price: $10.28 OGXI Score: -81.48

BUY PULLBACK

Recs

0
Member Avatar RBuskey106 (66.78) Submitted: 3/30/2012 12:06:02 PM : Outperform Start Price: $13.29 OGXI Score: -125.39

Cancer Bio---had a secondary offerring which dropped it down to these levels. Missed it the other day at a lower price, but feel confident in the long term prospects for the company.

Recs

1
Member Avatar tunget (< 20) Submitted: 2/28/2011 2:18:13 PM : Outperform Start Price: $15.71 OGXI Score: -138.31

OncoGenex today sports a $110 million enterprise value with less than 10 million shares outstanding. That's not very expensive for a company with a late-stage cancer drug, even one that's already partnered.

Recs

0
Member Avatar Mediajazzz (< 20) Submitted: 12/8/2010 5:46:17 PM : Outperform Start Price: $16.01 OGXI Score: -149.82

Higher volume makes this stock price increase

Recs

0
Member Avatar dboyer14 (< 20) Submitted: 7/18/2010 12:27:04 PM : Outperform Start Price: $12.41 OGXI Score: -170.83

This stock and company is undervalued based on available cash of $47 Million, will carry OGXI into 1012. Any good news on any of the three trials will bring the stock out of the down turn. Only 7.2 million shares outstanding fully diluted. High priced options expiring this quarter.

Recs

0
Member Avatar TheBestNeverRest (21.83) Submitted: 2/11/2010 8:10:48 PM : Outperform Start Price: $17.41 OGXI Score: -178.44

Easily a $20.00 plus stock given the deal with TEVA.

Recs

0
Member Avatar MJKpayday (99.77) Submitted: 10/11/2009 11:58:24 AM : Underperform Start Price: $24.24 OGXI Score: +215.96

Admittedly I've done little research, but UltraLong wrote a convincing case so I'm riding the coat tails.

Recs

5
Member Avatar number90 (< 20) Submitted: 7/22/2009 3:58:32 PM : Outperform Start Price: $21.44 OGXI Score: -215.72

Here are 10 reasons

1) Past experience with Sonus drugs are not relevant to current story -- ISIS licensed technology

2) Revenue doesn't matter when it comes to evaluating young biotechs in this stage of development (didn't think I'd have to mention that, but read other's comments here)

3) Significant overall survival advantage compared to docetaxel in controlled Ph2; this is as close as a gimme as you get for the ph3 hitting its endpoints. It really says a lot that the investigators crossed patients from the control arm to receive OGX-011, a drug with so little clinical experience (ie. its obvious this thing works!)

4) Extremely well executed ph2 trial; the fact that they teased out OS analysis should put faith back in company. They did very nice risk stratification in their analysis, that further reduces my risk in this investment :)

5) Not 'unproven', first in class drug. This is what oncologists want -- new weapons!

6) Despite recent run-up market cap is extremely low. Please look at competitors, CGRB is a good start (prostate cancer drug in similar stage of development, however no controlled trial and no known survival benefit).

7) SEC filing related to CGRB purchase said there were many suitors and multiple bids for company with one offer of 1B.

8) Rationale for very broad use in cancer lays the foundation for megablockbuster potential. This improves the efficacy of chemo! Lung and breast cancer are next.

9) Makes you wonder what other ISIS licensed technology is being developed in oncology (oh yeah OGXI owns that too)

10) Oncology due to lack of generic encroachment is a major therapeutic focus of big Pharma that must grow revenue with drugs outside of their own pipeline. Look at Pfizer story which wants Onc rev of greater than 25B in less than 10 years. They can not do it with their own/Wyeth pipeline and will need to purchase or license from other companies.

Recs

0
Member Avatar arboretum (28.45) Submitted: 6/29/2009 4:26:18 PM : Underperform Start Price: $22.50 OGXI Score: +214.07

ultralong

Recs

0
Member Avatar TMFBiologyFool (95.08) Submitted: 6/1/2009 1:30:52 PM : Outperform Start Price: $18.55 OGXI Score: -207.38

$100 million market cap is too low for a promising phase 2 drug.

Results 1 - 15 of 15

Featured Broker Partners


Advertisement